IAM
The Long Read
Life sciences companies are frequently on the front line when it comes to being flexible on IP and pricing, says Ben Bourke of Womble Bond Dickinson. The most recent example of this is Moderna Therapeutics’ promise not to enforce patents relating to its approved covid-19 vaccine. Such a response makes sense and should be favoured over government-led initiatives to circumvent IP rights. Read more here
MONDAY 5th April
A look at Chinese companies’ semiconductor patent holdings suggests that their best bet for gaining globally relevant IP in the space is to acquire it. However, that leaves them with a big problem. Read more here